top of page
kirabio-hero-4.png

Pipeline

kirabio-hero-1.jpg

Programmable Cell Therapies for the Toughest Cancers

​

Our programs focus on cancers where TME-driven suppression limits cell therapy efficacy—using allogeneic, multiplex-edited immune cells designed to evade those barriers and deliver durable responses.

 

KiraLOGIC guides edit selection based on the dominant suppressive signals in each disease.

​

Pipeline-2.png

*All programs use an allogeneic chassis and are optimized for TME resistance.

​More than a pipeline: a blueprint for defeating immune suppression

bottom of page